Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis This article recently appeared in the French-Canadian news publication “Le Soleil”. The origjnal article can be found here: https://www.lesoleil.com/affaires/2023/08/30/une-technologie-dici-pour-mieux-diagnostiquer-le-cancer-du-poumon-WMYOCY325FC65HU4ISBUQWJT5U/ The following is an AI translation of the text of the article to English: “Local Technology for Improved […]
BioMark appointS Kevin J. Cosgriff TO ITS STRATEGIC Advisory Team
Vancouver, British Columbia – (August 30th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that Vice Admiral Kevin Cosgriff will be joining BioMark’s Advisory team to support its innovation and […]
JAPAN PATENT OFFICE (JPO) ISSUEDD BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED LIQUID BIOPSY ASSAY
JAPAN PATENT OFFICE (JPO) ISSUED BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED LIQUID BIOPSY ASSAY New family of patent granted by Japanese Patent Office enhances BioMark’s global intellectual property position in lung cancer detection using urine as a convenient biological sample medium. Vancouver, British Columbia – (August 8th, 2023) – BioMark Diagnostics […]
BIOMARK Unveils SIGNIFICANT Scientific Advancements from its Leading liquid bioPSY TECHNOLOGY at ASCO 2023 Annual Meeting
BIOMARK Unveils SIGNIFICANT Scientific Advancements from its Leading liquid bioPSY TECHNOLOGY at ASCO 2023 Annual Meeting BioMark’s blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting. Vancouver, British Columbia – (June 5th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with […]
Biomark’s Dr. Maksymuik Presents at Prestigous ASCO Annual Meeting
Biomark’s Dr. Maksymuik Presents at Prestigous ASCO Annual Meeting Biomark Diagnostics, an early stage cancer research company based in Richmond, Canada, made a significant stride in its quest to advance cancer research by presenting at the prestigious ASCO (American Society of Clinical Oncology) 2023 Annual Meeting. The ASCO Annual Meeting is globally recognized as one […]
BIOMARK ANNOUNCES The U.S. Patent and Trademark Office Granted PATENT WITH CLAIMS COVERING ITS LUNG CANCER LIQUID BIOPSY ASSAY
The new family of patent granted by USPTO strengthens BioMark’s global intellectual property position in liquid biopsy and early cancer detection. Vancouver, British Columbia – (May 31st, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers […]
Press Release – BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2023
BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 New analyses from a large retrospective validation study of early lung cancer metabolomics panel, underscoring strength of BioMark’s liquid biopsy platform, to be presented. Vancouver, British Columbia – (May 3rd, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) […]
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS Vancouver, British Columbia – (March 16th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that novel liquid biopsy data presented this […]
BIOMARK PROVIDES THIRD QUARTER OPERATIONAL UPDATE AND 2023
BIOMARK PROVIDES THIRD QUARTER OPERATIONAL UPDATE AND 2023 Vancouver, British Columbia – (March 1st, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December […]
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that […]
